Let’s hope they manage to push the envelope and get AA access for Revascor use in stage 2 and 3 rather than just end stage heart failure patients, since the company have produced peer reviewed research published in peak journals both in the US s couple of years back and additionally, post the meeting with the FDA last year, in Europe in Dec 2024 about the spectacular results in the benefit of the treatment in ischemic heart failure with high inflammation. The former will provide a much larger market, rather than having to push outward the treatment from end stage back down to stage 2 and 3 patients.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)